Tuesday, 08/03/2010
|
Evaluating Cardiovascular Risk in Diabetes Clinical Trials: Lessons Learned from Saxagliptin
J Mark Donovan, Bristol-Myers Squibb
10:35 AM
|
Multiplicity Issues in Meta-Analyses to Rule Out an Unacceptable Cardiovascular Risk
Stefan Hantel, Boehringer Ingelheim Pharmaceuticals, Inc.
10:55 AM
|
Model Prior Choice and Multiplicity Correction in Bayesian Model and Variable Selection
Melanie Ann Wilson, Duke University; Merlise Clyde, Duke University; Edwin Iversen, Duke University
11:15 AM
|
On Optimal Grouping Strategies Using Parallel Gatekeeping Procedures
Haiyuan Zhu, Forest Research Institute
3:20 PM
|
A Multiplicity Strategy Incorporating Fixed Sequential, Hochberg, and Fallback Procedures
Duane Snavely, Merck & Co., Inc.; Kenneth Liu, Merck & Co., Inc.
3:35 PM
|
|